Intracerebral hemorrhage（ICH）is a cerebrovascular disease with high morbidity，mortality，and disability. As hematoma is the key driver of brain injury after ICH，early removal of hematoma components is crucial for preventing and reducing early brain damage following ICH. Existing treatments for ICH are limited in effectiveness，and recent preclinical trials have revealed some exciting findings，including an interesting new target—nuclear factor erythroid 2-related factor 2（Nrf2）. Nrf2 is a transcription factor that may play a neuroprotective role by activating cellular repair mechanisms through different pathways，and its therapeutic potential has attracted great interest in research. This article summarizes the role of Nrf2 and its agonists in post-ICH hematoma clearance and neuroprotection and the underlying mechanism.